EA201290360A1 - Гуманизированные антитела против il-22ra человека - Google Patents

Гуманизированные антитела против il-22ra человека

Info

Publication number
EA201290360A1
EA201290360A1 EA201290360A EA201290360A EA201290360A1 EA 201290360 A1 EA201290360 A1 EA 201290360A1 EA 201290360 A EA201290360 A EA 201290360A EA 201290360 A EA201290360 A EA 201290360A EA 201290360 A1 EA201290360 A1 EA 201290360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies against
humanized antibodies
against human
psoriasis
immune
Prior art date
Application number
EA201290360A
Other languages
English (en)
Other versions
EA021356B1 (ru
Inventor
Роланд Бекманн
Кэролайн Джонсон-Леджер
Original Assignee
Мерк Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Сероно С.А. filed Critical Мерк Сероно С.А.
Publication of EA201290360A1 publication Critical patent/EA201290360A1/ru
Publication of EA021356B1 publication Critical patent/EA021356B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Изобретение относится к гуманизированным антителам против человеческого IL-22RA и к их применению в лечении псориаза и других иммунноопосредованных заболеваний, таких как псориатический артрит и атопический дерматит.
EA201290360A 2009-11-19 2010-11-12 Гуманизированные антитела против il-22ra человека EA021356B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (2)

Publication Number Publication Date
EA201290360A1 true EA201290360A1 (ru) 2012-11-30
EA021356B1 EA021356B1 (ru) 2015-05-29

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290360A EA021356B1 (ru) 2009-11-19 2010-11-12 Гуманизированные антитела против il-22ra человека

Country Status (19)

Country Link
US (1) US8545844B2 (ru)
EP (1) EP2512511B1 (ru)
JP (1) JP5818804B2 (ru)
KR (1) KR20120098783A (ru)
CN (1) CN102665759B (ru)
AU (1) AU2010321047B2 (ru)
BR (1) BR112012012003A2 (ru)
CA (1) CA2778864C (ru)
EA (1) EA021356B1 (ru)
EC (1) ECSP12011980A (ru)
ES (1) ES2531996T3 (ru)
IL (1) IL219740A0 (ru)
IN (1) IN2012DN03362A (ru)
MX (1) MX2012005791A (ru)
NZ (1) NZ599438A (ru)
PE (1) PE20121560A1 (ru)
UA (1) UA105405C2 (ru)
WO (1) WO2011061119A1 (ru)
ZA (1) ZA201202793B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584157C (en) * 2004-10-22 2014-10-14 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
CN106536561A (zh) * 2014-05-01 2017-03-22 豪夫迈·罗氏有限公司 抗‑因子d抗体变体及其用途
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10654932B2 (en) * 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
CN114671940B (zh) * 2016-03-18 2023-09-26 舒泰神（北京）生物制药股份有限公司 神经生长因子突变体
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
TWI714854B (zh) * 2017-05-24 2021-01-01 財團法人生物技術開發中心 抗globo h之人類化抗體及其於治療癌症之用途
BR112019025105A2 (pt) 2017-06-30 2020-10-20 Zymeworks Inc. fabs quiméricos estabilizados
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2584157C (en) * 2004-10-22 2014-10-14 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006100582A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
KR101453570B1 (ko) * 2005-12-02 2014-10-22 제넨테크, 인크. Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법

Also Published As

Publication number Publication date
US8545844B2 (en) 2013-10-01
MX2012005791A (es) 2012-07-03
UA105405C2 (ru) 2014-05-12
BR112012012003A2 (pt) 2016-11-29
IN2012DN03362A (ru) 2015-10-23
CN102665759A (zh) 2012-09-12
JP5818804B2 (ja) 2015-11-18
ZA201202793B (en) 2013-06-26
ES2531996T3 (es) 2015-03-23
AU2010321047A1 (en) 2012-05-24
JP2013511267A (ja) 2013-04-04
PE20121560A1 (es) 2012-12-05
CN102665759B (zh) 2015-09-30
IL219740A0 (en) 2012-07-31
AU2010321047B2 (en) 2016-06-09
CA2778864A1 (en) 2011-05-26
EP2512511A1 (en) 2012-10-24
CA2778864C (en) 2017-06-27
WO2011061119A1 (en) 2011-05-26
EA021356B1 (ru) 2015-05-29
NZ599438A (en) 2013-12-20
US20120230990A1 (en) 2012-09-13
EP2512511B1 (en) 2015-01-07
KR20120098783A (ko) 2012-09-05
ECSP12011980A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201390493A1 (ru) Человеческие антитела к онкостатину м и способы их применения
EA201400875A1 (ru) Антитела к cd47 и способы их применения
JO3097B1 (ar) الأجسام المضادة c-Met
NZ599737A (en) Il-17a antagonists
EA201590402A1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
GB201109238D0 (en) Antibodies
TR201907261T4 (tr) DKK-1 antikorları.
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EA201891594A1 (ru) Антитела к il-17c
BR112013023513A2 (pt) anticorpos que ligam tgf-alfa e epiregulina
WO2011019636A3 (en) Methods and compositions for the treatment of cancers and pathogenic infections
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии
RU2013155843A (ru) Гуманизированное моноклональное антитело, специфичное к легумаину
CL2012001309A1 (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 (il-22ra) humana; polinucleotido que codifica tanto la cadena pesada como la cadena liviana de dicho anticuerpo; vector y celula hospedera que comprende dicho polinucleotido; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar soriasis, artritis soriatica o dermatitis atópica.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU